Shoklo Malaria Research Unit
Mae Sot, Changwat Tak, Thailand
NCT Number: NCT05557513
Thousands of migrants from Myanmar have arrived in Thailand for their safety, better living standards and employment opportunities. They are often in Thailand illegally and have poor access to the Thai health care system. This underutilization not only puts their health at risk but may also put the general public's health at risk. During the COVID-19 pandemic, migrants often have no access to diagnostic tests even though global health actors are focused on accelerating access to COVID-19 testing. SARS-CoV-2 testing is one of the most effective and necessary means of mitigating the COVID-19 pandemic.
The overarching goal of this study is to provide evidence on effectiveness and feasibility of community-based SARS-CoV-2 antigen rapid diagnostic test (Ag-RDT) application in the Myanmar migrant community, Tak Province along the Thai Myanmar border as part of test-trace-isolation strategies to fight COVID-19.
After the study has been completed, the study team will have evidence to inform policymakers on whether community based SARS-CoV-2 Ag-RDT test-trace-isolate strategy is effective and feasible to fight COVID-19 where there is limited or no access to COVID-19 testing in the Myanmar migrant communities.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Mae Sot, Changwat Tak, Thailand
This study plan to recruit people who are living in the Maramat and Pohphra Myanmar migrant community or returning to community from outside.
This study includes seroprevalence survey (secondary objective) at the beginning and at the post-intervention of study to estimate the percentage of people in a population who have antibodies against SARS-CoV-2 by capillary blood collection from finger prick. This secondary objective will be achieved through a substudy. In the substudy, 427 participants will be studied from 7 clusters that will be randomly sampled from the parent study for the Ag RDT arm and similarly 427 participants will be studied from 7 clusters that will be randomly sampled from the parent study for the No Ag RDT arm. There will be two cross-sectional surveys in each of these two arms one at baseline and the other at post-intervention. The aim will be to compare the post-intervention percentage of people in a population who have antibodies against SARS-CoV-2 by capillary blood collection from finger prick between the two arms.
The two arms of the substudy will be managed as follows:
One arm (Arm 1): Symptomatic /suspected COVID-19 participant or close contact/family members of COVID-19 patient will be tested with Ag RDT and also involve in awareness-raising campaign with mask distribution.
One arm (Arm 2): No community based Ag RDT testing but there has routine ATK or RT-PCR test by Thai health authorities if local health volunteer finds symptomatic or suspected COVID-19 or close contact with positive cases in their villages. The participant also involves in awareness-raising campaign with mask distribution.
Ten focus group discussion (FGD) with community members will be conducted to find out the attitudes and perception of community members on the use of community based SAR COV2 Ag-RDTs testing in Myanmar migrant community for prevention control of COVID-19 in the study area.
The overarching goal of this study is to provide evidence on effectiveness and feasibility of community-based SARS-CoV-2 antigen rapid diagnostic test (Ag-RDT) application in the Myanmar migrant community, Tak Province along the Thai Myanmar border for test-trace-isolation strategies to fight COVID-19.
After the study has been completed, depending upon the study finding, study team believe that study team can propose to policymakers to recognize the effectiveness and feasibility of community-based SARS-CoV-2 Ag-RDT's test-trace-isolate strategies to fight COVID-19 where there is limited or no access to COVID-19 testing in the Myanmar migrant communities
This study was funded by The Foundation for Innovative New Diagnostics (FIND). The grant reference number is U-22008
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
note: *Symptomatic or suspected COVID-19: Acute onset of ANY THREE OR MORE of the following signs or symptoms: Fever, cough, general weakness/fatigue1, headache, myalgia, sore throat, coryza, dyspnoea, anorexia/nausea/vomiting1, diarrhoea, altered mental status (1 Signs separated with slash (/) are to be counted as one sign) Reference: WHO-2019-nCoV-Surveillance_Case_Definition-2020.2-eng (5).pdf
note: **1 Person who stayed close to or had conversation with COVID-19 patient(s) for >5 minutes, or was exposed to the patient's cough or sneeze; 2 Individual who stayed in enclosed spaces with poor ventilation together with COVID-19 patient(s) for >30 minutes, for instance, in air-conditioned bus, commuter vane, or air-conditioned room; Reference: g_HCWs_3Mar22.pdf (moph.go.th)
Device Name: STANDARD Q COVID-19 Ag Test Manufactured by SD Biosensor, Inc., Korea
Purpose: To detect COVID-19 (Its manufacture specification sensitivity was at 84.97% and specificity 98.4%)
Time frame: through study completion, an average of 3 months
The number of cases per 1,000 will be estimated and summarised per group/arm and will compared between groups
Time frame: through study completion, an average of 3 months
Seroprevalence of SAR COV2 antibody in each of the groups at baseline and at post-intervention surveys.
Time frame: through study completion, an average of 3 months
Attitudes of community participants towards community base SAR COV2 Ag-RDTs use.
Time frame: through study completion, an average of 3 months
Perception of community participants towards community base SAR COV2 Ag-RDTs use.
University of Oxford
Other
Evaluating the Effectiveness and Feasibility of Community Based SARS-CoV-2 Antigen Rapid Diagnostic Testing (Ag-RDT) in the Myanmar Migrant Community, Tak Province Along the Thai Myanmar Border for Controlling Coronavirus Transmission
Acronym: CATK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05096260
COVID-19, COVID-19 Pandemic
Ann Arbor, Michigan, United States
View Trial DetailsNCT05188651
COVID-19, COVID-19 Pandemic
Roma, RM, Italy
View Trial DetailsNCT07436572
COVID-19, COVID-19 Pandemic
Gaziantep, Turkey (Türkiye)
View Trial DetailsNCT06036134
Behavior, COVID-19
Phoenix, Arizona, United States
View Trial Details